Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13734237 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL13737164 | 1.00 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL23048922 | 0.87 | KDM1A (0.45) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL22199165 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL2630501 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL2630499 | 0.86 | NFKB1 (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL25041953 | 0.85 | BTK (0.46) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL24831927 | 0.84 | BTK (0.44) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL15122679 | 0.84 | BTK (0.44) | BTKNFKB1NFKB2RELAKDM1A | |
| SCHEMBL22680983 | 0.82 | DRD2 (0.44) | BTKNFKB1NFKB2RELAKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11241430-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3795553-A1 | METHODS OF SYNTHESIS OF (1R,2R,5R)-5-AMINO-2-METHYLCYCLOHEXANOL HYDROCHLORIDE AND INTERMEDIATES USEFUL THEREIN | Celgene Corporation (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2012145569-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-26 | — | — | WO | disclosed |
| US-7241811-B2 | E.g., 1-(pyridin-4-ylcarbamoyl)-1,2,3,6- tetrahydropyridine hydrochloride; therapy and prophylaxis of amnesia or dementia | ASTELLAS PHARMA INC. (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7037942-B2 | Amide compounds for the potentiation of cholinergic activity | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060058396-A1 | Amide compounds for the potentiation of cholinergic activity | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1159258-B1 | AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-20040048904-A1 | Amide compounds for the potentiation of cholinergic activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| US-6664293-B2 | For treatment and/or prevention of disorders in the central nervous system, particularly amnesia, dementia, Alzheimer's dementia | FUJIWAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030096847-A1 | Amide compounds for the potentiation of cholinergic activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1159258-A1 | AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000051970-A1 | AMIDE COMPOUNDS FOR THE POTENTIATION OF CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | BTK 1113/4885NFKB1 1599/4885NFKB2 1054/4885 |
| US-20040048904-A1 | Amide compounds for the potentiation of cholinergic activity | CHAT, CHRM2, CHRNA2 | BTK 3886/4885NFKB1 2046/4885NFKB2 1307/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-11241430-B2 | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | TERT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT | BTK 1729/4885NFKB1 2697/4885NFKB2 3807/4885 |
| US-20060058396-A1 | Amide compounds for the potentiation of cholinergic activity | CHRM2, CHRM1, CHAT | BTK 4053/4885NFKB1 1823/4885NFKB2 1167/4885 |
| US-20030096847-A1 | Amide compounds for the potentiation of cholinergic activity | CHAT, CHRM2, CHRNA2 | BTK 3886/4885NFKB1 2046/4885NFKB2 1307/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | BTK 2349/4885NFKB1 483/4885NFKB2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.